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Hyperinsulinaemia due to inhibition of 5a-reductases is ameliorated by liver-selective glucocorticoid receptor antagonism in diet-induced obesity Tracy C S Mak, Dawn E W Livingstone, Brian R Walker & Ruth Andrew University of Edinburgh, Edinburgh, UK. Background 5a-reductase 1 (5aR1) metabolises steroids such as glucocorticoids and androgens, and is highly expressed in murine liver. Genetic disruption of 5aR1 leads to adverse metabolic changes in mice. We hypothesised that dutasteride, a 5aR inhibitor, induces insulin resistance in mice, as in humans, and this effect is underpinned by increased hepatic glucocorticoid action; an experimental paradigm was set up using A-348441, a liver-selective glucocorticoid receptor (GR) antagonist, and then utilised to assessed the contribution of increased hepatic glucocorticoid action to the metabolic consequences of dutasteride. Methods C57BL6/J male mice (nZ8-15/group; age 12 weeks) were given high fat (HF), HF with A-348441 (KaroBio), HFCdutasteride (Dut), or HFCDutCA-348441 diet for 4 weeks. Glucose tolerance tests (GTT) were performed at week 3, with mice culled at week 4. Plasma insulin and corticosterone were measured by ELISA and plasma glucose spectrophotometrically. Background Obesity is a global health concern. Elevating energy expenditure (EE) would be a highly effective treatment approach to treat obesity but no current drugs can safely achieve this. Cold exposure potently increases EE through brown adipose tissue (BAT) thermogenesis in humans. Glucagon elevates EE via BAT in rodents but the mechanism in humans is unknown. We investigated for the first time the mechanism by which glucagon increases EE in humans. Methods Eleven volunteers underwent measurement of EE using an indirect calorimeter at the start and end of three interventions: i) cold exposure; ii) control (vehicle) infusion at 23 8C; and iii) glucagon infusion at 23 8C. On each visit thermal images of the neck were taken -an increase in temperature is a non-invasive measure of increased BAT activity. All 11 volunteers also underwent a FDG PET-CT scan with cold exposure. In those in which this confirmed cold-induced BAT activity (nZ8), they had a second PET-CT scan with either vehicle (nZ4) or glucagon (nZ4) infusion (23 8C). Results EE rose by 14% with cold exposure and 15% following glucagon infusion (P!0.05 vs control). BAT depots identified on the cold scan had significantly (4!) higher metabolic activity than on the vehicle or glucagon infusion scans, which were not significantly different from each other. There was a 0.31 8C rise (P!0.001) in neck temperature on thermal images after cold exposure in the BAT positive cohort but not after glucagon or vehicle infusion. Conclusions Glucagon and cold exposure have a similar effect in stimulating energy expenditure but glucagon has no effect on the metabolic activity of classical adult supraclavicular BAT compared with cold exposure. This information is of importance to the development of better targeted and safe treatments designed to combat obesity through upregulation of energy expenditure. Specific variations in the human glucocorticoid receptor (GR) gene associate with increased cardiovascular disease risk. GR signalling is essential for cardiac maturation in utero and adult mice with cardiomyocyte and vascular smooth muscle deletion of GR (SMGRKO mice) have cardiac hypertrophy, fibrosis and impaired function. Intriguingly, levels of left ventricle (LV) mRNA encoding the mineralocorticoid receptor (MR), which is pro-fibrotic in heart, rise postnatally in SMGRKO mice in parallel with the development of cardiac fibrosis. Here, the benefit of MR antagonism in limiting cardiac fibrosis was assessed in SMGRKO mice. SMGRKO mice (generated via SM22a-Cre mediated deletion of GR) and control (CreK) littermates were treated from birth with vehicle or 20 mg/kg per day spironolactone, an MR antagonist, administered in the drinking water to lactating dams until weaning then to offspring (nZ10-13/group). At 8 weeks of age, hearts were collected for histology and mRNA profiling. Data were analysed by twoway ANOVA with Tukey's multiple comparisons test. Heart weight in male SMGRKO mice was higher than controls irrespective of spironolactone treatment (P!0.01). Interestingly, spironolactone modestly reduced heart weight in both genotypes (P!0.05). PicroSirius Red staining showed greater collagen levels in LV of SMGRKO mice (P!0.001); spironolactone treatment reduced the magnitude of this genotypic difference. Although spironolactone did not prevent the increase in LV levels of mRNA encoding MR or profibrotic factors (connective tissue growth factor, collagen1a2 and collagen3a1) in SMGRKO mice, it did attenuate collagen1a2 mRNA increases (P!0.05).
In conclusion, the modulatory effects of spironolactone on pro-fibrotic signalling suggest that elevated MR contributes to the pro-fibrotic cardiac phenotype discovered in SMGRKO mice. Consequently, MR antagonism may benefit individuals with particular variants of the GR gene. Spironolactone effects on heart weight indicate a role for MR in early life cardiac growth and SMGRKO mice are, potentially, a useful new model to investigate MR-dependent cardiac fibrosis. DOI: 10.1530/endoabs.38.OC4.6 Thyroid and parathyroid OC5.1
Functional consequences of germline mutations in a novel non-RET medullary thyroid cancer susceptibility gene Martin Read with predisposition to MTC in whom no RET mutation has been identified (non-RET MTC). Recently, we identified novel mutations in a single gene termed MTC2 in non-RET MTC individuals by whole exome sequencing. The precise role of these MTC2 germline mutations in MTC tumorigenesis is however unclear. Here, we examined the functional consequences of MTC2 mutants V128L and G318Afs*22 to determine their roles in MTC. Luciferase (LUC) reporter assays showed that MTC2-V128L retained transcriptional activity with a significant increase in LUC activity in response to steroid hormone receptoragonist DPN in HCT116 (3.7-fold; P!0.01) and MCF-7 (1.8-fold; P!0.05) cells. In contrast, MTC2-G318Afs*22 was incapable of inducing LUC activity in either cell line (PZNS). Furthermore, MTC2-G318Afs*22 failed to inhibit ERadriven luciferase activity in response to either 17b-estradiol (E 2 ) or ERa-agonist PPT, or restrain ERa-driven proliferation of MCF7 cells (PZNS compared to ERa alone). In contrast, WT MTC2 and MTC2-V128L inhibited ERa-driven LUC activity (O60%; P!0.01) and cell proliferation (O30%; P!0.05). As RET expression is known to be stimulated by oestrogen, we then determined the influence of MTC2 mutants on RET in E 2 -and PPT-treated HCT116 cells. In contrast to WT MTC2, MTC2-G318Afs*22 was unable to oppose ERastimulation of the RET proto-oncogene at both the mRNA and protein level (PZNS compared to ERa alone). Treatment with anti-oestrogen 4-hydroxytamoxifen was however capable of inhibiting E 2 -induced RET mRNA expression in cells with MTC2-G318Afs*22. Together these data indicate an emerging role for MTC2 as a novel susceptibility gene in non-RET MTC development, especially as MTC2 mutant G318Afs*22 was associated with higher RET levels. These results also suggest that anti-oestrogens might represent a promising therapeutic strategy for MTC individuals with defective MTC2. Background Congenital, isolated, central, hypothyroidism (CCH), is rare and evades diagnosis on TSH-based congenital hypothyroidism screening programmes in the UK. Genetic ascertainment is therefore paramount in enabling prompt diagnosis and treatment of familial cases. Recognised causes include TSHB and IGSF1 gene defects, with only two previous reports of biallelic, highly disruptive (nonsense; R17X, in-frame deletion and missense; p.S115-T117delCT118), mutations in the TRHR gene. Here, we describe the first homozygous missense mutation in TRHR, associated with a typical phenotype. Case A female infant from a consanguineous Pakistani family, presented with prolonged neonatal jaundice and was found to have central hypothyroidism (TSH 2.2 mU/l, NR 0.4-3.5 and free T 4 7.9 pmol/l, NR 10.7-21.8), with otherwise normal pituitary function. With TSHB or IGSF1 mutations being usually associated with profound or X-linked CCH, a TRHR mutation was sought. Results Sequencing identified a homozygous mutation (P81R) in TRHR, substituting arginine for a proline residue in transmembrane helix 2 (TM2) which is highly conserved amongst G-protein coupled receptors (GPCRs). Functional studies showed that although the mutant receptor was expressed and localised to the cell membrane normally, its ability to bind radiolabelled TRH and signal via Gqa was markedly impaired, likely due to disruption of structure of TM2. Conclusion We describe the first deleterious, missense TRHR defect associated with moderate CCH. Importantly, the location of the mutated amino acid (proline 81) highlights a previously unanticipated functional importance of the TM2 in mediating hormone binding and receptor activation. Future identification of other, naturallyoccurring, TRHR mutations may map the molecular basis of ligand binding and activation of TRHR which are poorly understood. DOI: 10.1530/endoabs.38.OC5.2
